Related Experiment Video
Updated: May 19, 2026

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
Published on: May 25, 2017
In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile
Manoj Kumar1, Tarun Mathur, Tarani K Barman
1Department of Infectious Diseases, New Drug Discovery Research, Ranbaxy Research Laboratories, Gurgaon, India.
Abstract:
The MIC(90) of RBx 14255, a novel ketolide, against Clostridium difficile was 4 μg/ml (MIC range, 0.125 to 8 μg/ml), and this drug was found to be more potent than comparator drugs. An in vitro time-kill kinetics study of RBx 14255 showed time-dependent bacterial killing for C. difficile. Furthermore, in the hamster model of C. difficile infection, RBx 14255 demonstrated greater efficacy than metronidazole and vancomycin, making it a promising candidate for C. difficile treatment.
Related Concept Videos
Antimicrobial Effectiveness
Clinical Significance of Antibiotic Resistance
